The price of Bluebird bio Inc (NASDAQ: BLUE) closed at $1.75 in the last session, up 19.86% from day before closing price of $1.46. In other words, the price has increased by $+0.2900 from its previous closing price. On the day, 29639054 shares were traded.
Ratios:
We take a closer look at BLUE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.
On December 08, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $3 to $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 05 when Vittiglio Joseph sold 5,217 shares for $0.90 per share. The transaction valued at 4,708 led to the insider holds 44,783 shares of the business.
Klima Thomas J sold 2,714 shares of BLUE for $2,449 on Feb 05. The insider now owns 129,413 shares after completing the transaction at $0.90 per share. On Feb 05, another insider, Obenshain Andrew, who serves as the President and CEO of the company, sold 1,879 shares for $0.90 each. As a result, the insider received 1,696 and left with 286,093 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 335.37M and an Enterprise Value of 464.78M. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.52 while its Price-to-Book (P/B) ratio in mrq is 0.84. Its current Enterprise Value per Revenue stands at 21.39 whereas that against EBITDA is -3.53.
Stock Price History:
Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.88. The 50-Day Moving Average of the stock is 1.4006, while the 200-Day Moving Average is calculated to be 2.9573.
Shares Statistics:
According to the various share statistics, BLUE traded on average about 13.18M shares per day over the past 3-months and 8.03M shares per day over the past 10 days. A total of 192.74M shares are outstanding, with a floating share count of 189.78M. Insiders hold about 1.54% of the company’s shares, while institutions hold 67.18% stake in the company. Shares short for BLUE as of Jan 31, 2024 were 27.5M with a Short Ratio of 2.09, compared to 24.09M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 14.27% and a Short% of Float of 15.23%.
Earnings Estimates
The company has 11 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.38 and a low estimate of -$0.98, while EPS last year was $0.38. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.24 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1 and -$2.83 for the fiscal current year, implying an average EPS of -$1.84. EPS for the following year is -$1.77, with 13 analysts recommending between -$0.92 and -$3.09.
Revenue Estimates
According to 10 analysts, the current quarter’s revenue is expected to be $16.62M. It ranges from a high estimate of $21.5M to a low estimate of $11.51M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $62k, an estimated increase of 26,706.50% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $20.12M, an increase of 745.00% less than the figure of $26,706.50% in the same quarter last year. There is a high estimate of $29.2M for the next quarter, whereas the lowest estimate is $12.2M.
A total of 13 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $49M, while the lowest revenue estimate was $33.18M, resulting in an average revenue estimate of $40.56M. In the same quarter a year ago, actual revenue was $3.6M, up 1,027.60% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $126.3M in the next fiscal year. The high estimate is $173M and the low estimate is $56.72M. The average revenue growth estimate for next year is up 211.40% from the average revenue estimate for this year.
